275 related articles for article (PubMed ID: 16272626)
1. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
[TBL] [Abstract][Full Text] [Related]
2. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
[TBL] [Abstract][Full Text] [Related]
3. [Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride].
Ito M; Mochizuki T; Koike T; Hashimoto N; Fukazawa S; Akatsuka T; Niida Y; Tozawa S; Yasuda T; Sato M
Clin Calcium; 2005 Sep; 15 Suppl 1():11-13; discussion 13-4. PubMed ID: 16279016
[TBL] [Abstract][Full Text] [Related]
4. [Clinical analysis of time-course changes in minerals and parathyroid hormone levels during treatment with phosphate binders in hemodialysis patients with secondary hyperparathyroidism].
Yokoyama T; Onodera Y; Mano T
Clin Calcium; 2005 Sep; 15 Suppl 1():125-30; discussion 130-1. PubMed ID: 16272644
[TBL] [Abstract][Full Text] [Related]
5. [Control of calcium and phosphate in hemodialysis patients].
Eriguchi R; Takei S; Satou Y
Clin Calcium; 2005 Sep; 15 Suppl 1():132-7; discussion 137. PubMed ID: 16272645
[TBL] [Abstract][Full Text] [Related]
6. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
Chudek J; Piecha G; Kokot F; Wiecek A
J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
[TBL] [Abstract][Full Text] [Related]
7. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy.
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S16-21. PubMed ID: 16109136
[TBL] [Abstract][Full Text] [Related]
8. [Sevelamer hydrochloride and vitamin D for controlling serum calcium, phosphorus and bone metabolism in patients undergoing hemodialysis].
Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
Clin Calcium; 2005 Sep; 15 Suppl 1():192-9. PubMed ID: 16279024
[No Abstract] [Full Text] [Related]
9. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
[TBL] [Abstract][Full Text] [Related]
10. [Clinical effect of introduction of sevelamer hydrochloride in patients with hyperphosphatemia undergoing maintenance dialysis].
Tahara H; Tsujimoto Y; Shouji T; Inaba M; Tabata T; Nishizawa Y
Clin Calcium; 2005 Sep; 15 Suppl 1():173-9. PubMed ID: 16279021
[No Abstract] [Full Text] [Related]
11. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
[TBL] [Abstract][Full Text] [Related]
12. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
14. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.
Chertow GM; Dillon M; Burke SK; Steg M; Bleyer AJ; Garrett BN; Domoto DT; Wilkes BM; Wombolt DG; Slatopolsky E
Clin Nephrol; 1999 Jan; 51(1):18-26. PubMed ID: 9988142
[TBL] [Abstract][Full Text] [Related]
16. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
17. [Role of sevelamer hydrochloride in the Coronary Artery Calcification Index].
Tsuruta Y; Kaneshiro K; Narita Y; Oobayashi T; Fujii M; Narita M; Sasai K; Yoshimata T; Watanabe Y; Maeda K
Clin Calcium; 2005 Sep; 15 Suppl 1():200-5. PubMed ID: 16279025
[No Abstract] [Full Text] [Related]
18. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
20. Introduction to sevelamer hydrochloride and its clinical effects.
Tahara H; Tsujimoto Y; Shoji T; Inaba M; Tabata T; Nishizawa Y
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S2-6. PubMed ID: 16109137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]